) announced additional positive data from its phase I program on
OMS824. OMS824 is Omeros' lead candidate in its phosphodiesterase
10 (PDE10) program.
ACTELION LTD (ALIOF): Get Free Report
AMAG PHARMA INC (AMAG): Free Stock Analysis
ISIS PHARMACEUT (ISIS): Free Stock Analysis
OMEROS CORP (OMER): Free Stock Analysis
To read this article on Zacks.com click here.
The study evaluated the extent to which a higher dose of OMS824
binds to PDE10. The additional data revealed that an average of
63% engagement with PDE10 was observed in patients treated with
OMS824. The level of engagement was significantly higher in the
trial with lesser side effects compared to any other PDE10
inhibitor in development.
Moreover, the candidate did not show any dose-limiting side
effects, which was seen in other PDE10 inhibitors. OMS824 was
well tolerated during the trial with the only side effect of mild
In May 2013, Omeros had reported that OMS824 achieved high target
occupancy without causing movement disorders seen with other
PDE10 inhibitors. The positron emission tomography (PET) study
evaluating OMS824 at lower doses revealed target engagement of
about 50%, more than other PDE10 inhibitors. Omeros now intends
to evaluate a higher dose of OMS824 in the PET study.
We note that Omeros is preparing to initiate a phase II study on
OMS824 for the treatment of Huntington's disease. The study is
expected to commence by year end. Last month, the candidate was
granted Orphan Drug Designation by the U.S. Food and Drug
Administration for this indication. A Fast Track application is
also under review in the U.S. for OMS824 in the Huntington's
Omeros is also evaluating OMS824 for the treatment of
schizophrenia in a phase II study. We are encouraged by Omeros'
progress with OMS824.
Omeros at present carries a Zacks Rank #4 (Sell). Stocks such as
MAG Pharmaceuticals, Inc.
Isis Pharmaceuticals, Inc.
) currently look better positioned in the pharma space with a
Zacks Rank #1 (Strong Buy).